secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029040
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025
--------------------------------------------------------------------------------

- Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.
- Revenue fell to $1.0M in 2024 from $4.0M in 2023; no Q4 revenue.
- Cash $1.4B at Dec 31, 2024, up from $558.6M; includes $925M in equity financings.
- PDUFA target action date for paltusotine (acromegaly) set for Sept 25, 2025.
- Plan to start Phase 3 paltusotine in carcinoid syndrome Q2 2025 and four IND filings in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025029040/0000950170-25-029040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025029040/crnx-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer